Prenatal Screening Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033

The Prenatal Screening Market Report Overview

The prenatal screening market size was $669.3 million in 2023 and will drive the market growth at a CAGR of more than 1% from 2023 to 2033. Pre-natal screening describes tests that detect potential problems that affect the viability and development of the fetus. These tests use both less invasive and more invasive sampling techniques.

Prenatal Screening Market Outlook 2023-2033 ($ Million)

Buy the Full Report for More Insights on the Prenatal Screening Market Forecast, Download a Free Sample Report

The prenatal screening market research report identifies quantitative market trends within in vitro diagnostics areas. The report offers regional quantitative and qualitative data highlighting the sales in major markets. The model also covers in detail the effects of COVID-19 on the prenatal screening market for 2020 and beyond. Furthermore, the report provides prenatal screening market share by a company that will help in identifying untapped market opportunities.

Prenatal screening Market Segments

The key segments in the prenatal screening market are alpha-fetoprotein (AFP) tests, free beta human chorionic gonadotropin (hCG) Tests, Inhibin A tests, non-invasive prenatal testing (NIPT), pregnancy associated plasma protein A (PAPP-A) tests, total human chorionic gonadotropin (hCG) tests, and unconjugated estriol (uE3) tests. In 2023, non-invasive prenatal testing (NIPT) accounted for the highest share of the prenatal screening market.

Non-invasive prenatal screening is a method that determines the risk of genetic abnormalities in the fetus by analyzing the cfDNA. During pregnancy, the fetal cells when die off and get degraded, release their content including DNA into the maternal bloodstream through the placenta.

Prenatal Screening Market Analysis by Segments, 2023 (%)

Buy the Full Report for More Insights into the Prenatal Screening Market Segment, Download a Free Sample Report

Regional Analysis of the Prenatal Screening Market

The key regions in the prenatal screening market are Asia-Pacific, Europe, the Middle East, and Africa. North America and South and Central America are other leading regional markets. In 2023, the North American prenatal screening market was the leading regional segment.

Rates of prenatal screening are relatively high in the US and Canada, with most women being screened using maternal serum markers. While live birth rates are predicted to rise during the forecast period, competitive pricing pressures and the growing adoption of NIPT in the US mean that the North American prenatal screening market is expected to decline.

Prenatal Screening Market Analysis by Regions, 2023 (%)

Buy the Full Report for More Regional Insights into the Prenatal screening Market, Download A Free Sample Report

Prenatal Screening Market – Competitive Landscape

In 2023, Illumina Inc.’s prenatal screening market share was the highest

The major players in the prenatal screening market are:

• Illumina Inc
• BGI Genomics Co Ltd
• Yourgene Health Plc
• Eurofins Scientific SE
• Agilent Technologies Inc

Companies may wish to invest in training and education schemes as a competitive strategy. This can help promote Down Syndrome disease awareness in countries with the potential to implement more comprehensive screening strategies. Additionally, these companies may want to familiarize physicians with their brand or type of devices through such training and education programs. In addition, companies that manufacture second-trimester test products may have a desire to invest in developing devices. These devices should give more accurate results for high-risk patient groups and high maternal age groups. Simultaneously, they must maintain a low price point.

Prenatal Screening Market Analysis by Companies, 2023 (%)

Buy the Full Report for More Company-Wise Insights into the Prenatal screening Market, Download a Free Sample Report

Prenatal Screening Market Dynamics

• Trends: Many countries are gradually introducing a non-invasive prenatal testing method (NIPT) of prenatal screening. NIPT is the subject of more than 10 completed or ongoing clinical trials in China, the United Kingdom, and the United States. Currently, NIPT is available in more than 60 countries. It is considered more sensitive and represents an attractive alternative to both maternal serum screening and invasive follow-up diagnostic techniques.
• Future Outlook: Globally, the prevalence of Down syndrome is rising along with public awareness of the condition and the need for prenatal screening. Sales of prenatal screening devices depend upon disease incidence, live birth rate, and number of pregnant women. GlobalData expects the prenatal screening market to be dominated by NIPT within the forecast period.

Purchase the Complete Report for Additional Insights on the Prenatal screening Market Dynamics, Get a Free Sample Report Here

Segments Covered in this Report

Prenatal Screening Market Segment Outlook ($ Million, 2015-2033)

• Alpha-Fetoprotein (AFP) Tests
• Free Beta Human Chorionic Gonadotropin (hCG) Tests
• Inhibin A Tests
• Non-invasive prenatal testing (NIPT)
• Pregnancy Associated Plasma Protein A (PAPP-A) Tests
• Total Human Chorionic Gonadotropin (hCG) Tests
• Unconjugated Estriol (uE3) Tests

Prenatal screening Regional Outlook ($ Million, 2015-2033)

• Asia-Pacific
• Europe
• Middle East and Africa
• North America
• South and Central America

Key Inclusions of the market model are:

The prenatal screening market research report includes an insightful review of the key industry trends.

• The prenatal screening market report offers an annualized market revenue by segment and market outlooks from 2015-2033.
• The report also includes market-level data on units, average selling prices, and market values.

Regional, Country, and Global Prenatal Screening Market Insights:

• The prenatal screening market share report offers qualitative insights into global and regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
• Prenatal screening market SWOT analysis.
• The report provides trends and prenatal screening market competitive dynamics.

Buy the Full Report for More Insights on the Prenatal screening Market Share, Download a Free Sample Report

Learn about consumer behavior through the detailed overview of segments and the healthcare system. The report also offers information on reimbursement policies and the regulatory landscape.

• Country-specific overview of the healthcare system.
• Country-specific reimbursement policies.
• Country-specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide an extensive and accurate overview of the market. These syndicated models include demand and supply-side primary sources including Key opinion leaders. In addition, determine market trends through real-world data sources including databases of government procedures and hospital purchasing.

Companies Covered: Illumina Inc, BGI Genomics Co Ltd, Yourgene Health Plc, Eurofins Scientific SE, Agilent Technologies Inc, F. Hoffmann-La Roche Ltd, Revvity Inc, Danaher Corp, Abbott Laboratories, Siemens AG, Quidelortho Corp, Thermo Fisher Scientific Inc, Tosoh Corp, and others.

Countries Covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

• Extensive coverage of the prenatal screening market under development.
• An exhaustive list of major pipeline products and their details, including product description, licensing and collaboration details, and other developmental activities.
• Reviews of major players involved in the development of the prenatal screening market and lists all their pipeline projects.
• Coverage of pipeline products based on various stages of development ranging from early development to approved/issued stage.
• Key clinical trial data of ongoing clinical trials specific to pipeline products.
• Recent developments in the segment/industry.

Reasons to Buy

• Understand the COVID-19 impact on prenatal screening.
• Design your licensing strategies through a review of products, technologies, and companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving prenatal screening.
• Understand the trends, innovative product launches, technologies, segments, and companies that will impact the market in the future.
• Formulate effective sales and marketing strategies with a detailed evaluation of prenatal screening market share by company. Identify strong competitors and create winning strategies to stand out in the global prenatal screening market.
• Track regional prenatal screening market sales as well as country-specific transactions from 2015-2033.
• Organize your sales and marketing efforts by identifying the global prenatal screening market segments that present maximum opportunities. Such details will help to make investments and strategic partnerships.